Research & Studies
Share your love
MacTel Decoded: Rethinking Conventional Approaches with Novel Neuroprotective Strategies | Ophthalmology Times
Thanks for your interest in this podcast. Please read this important program information before listening. Episode Description In this podcast, experts Charles C. Wykoff, MD, PhD, FASRS; Jed H. Assam, MD, MS; Diana V. Do, MD; and Dante Pieramici, MD,…
When Mites Meet Their Match: Empowering Patients With Targeted Treatment for Demodex Blepharitis | Ophthalmology Times
Thanks for your interest in this podcast. Please read this important program information before listening. Episode Description In this podcast, expert Mile Brujic, OD, FAAO, discusses the burden, diagnosis, and management of Demodex blepharitis, highlighting a recently approved targeted treatment…
International Glaucoma Symposium highlights the meeting point of practice and technology | Ophthalmology Times
The 2nd International Glaucoma Symposium underscores how AI and advanced imaging are becoming integral to modern glaucoma diagnosis and management. (Image credit: AdobeStock/OngCaLucK) The International Glaucoma Symposium was created to close the gap between cutting-edge research and real-world clinical decision-making…
FDA approves carbachol–brimonidine eye drop for presbyopia following phase 3 BRIO trials | Ophthalmology Times
FDA approval of YUVEZZI marks the first dual-agent, daily eye drop option for adults seeking non-invasive presbyopia treatment. (Image credit: Ophthalmology Times) The FDA has approved a fixed-dose ophthalmic combination of carbachol and brimonidine tartrate (YUVEZZI; Tenpoint Therapeutics) for the…
FDA Type C meeting supports phase 2b/3 pathway for urcosimod in neuropathic corneal pain | Ophthalmology Times
(Image Credit: AdobeStock/OlegKachura) Editor’s Note: This content was generated with the assistance of AI. A US Food and Drug Administration (FDA) Type C meeting has clarified key elements of the late-phase development pathway for urcosimod, an investigational topical therapy for neuropathic…
FDA approves NDA labeling supplement allowing re-administration of iDose TR | Ophthalmology Times
The US Food and Drug Administration has approved an NDA labeling supplement from Glaukos enabling the re-administration of iDose TR (travoprost intracameral implant) using a repeat treatment protocol. According to the company, under the updated labeling for iDose TR, physicians may now re-administer iDose…
Belite Bio completes enrollment in phase 2/3 DRAGON II trial for STGD1 | Ophthalmology Times
(Image Credit: AdobeStock/khunkornStudio) Belite Bio has completed enrollment in its phase 2/3 DRAGON II clinical trial evaluating tinlarebant for the treatment of Stargardt disease type 1 (STGD1). Tinlarebant is a novel oral therapy intended to reduce the accumulation of vitamin…
Opus Genetics launches phase 1/2 MERTK gene therapy trial | Ophthalmology Times
(Image Credit: AdobeStock/Dragon Claws) Opus Genetics has launched its clinical trial evaluating OPGx-MERTK gene therapy for MERTK-related retinitis pigmentosa (RP). The trial is funded through Abu Dhabi’s Healthcare Research and Innovation Fund. OPGx-MERTK is an investigational adeno-associated virus (AAV)-based gene…
Study finds artificial tear viscosity and shear-thinning behavior vary by formulation | Ophthalmology Times
(Image Credit: ADobeStock/New Africa) A large international study1 that evaluated the properties of dry eye drops showed that the commercially available formulations exhibited varying degrees of shear-thinning behavior, which affects the impact on the ocular surface. Ulrich Graf, PhD, the…
Myra Vision treats first patient in ADAPT trial of Calibreye TGT Surgical System | Ophthalmology Times
(Image Credit: AdobeStock/andrew_shots) Myra Vision has treated the first patient in its ADAPT clinical study evaluating the Calibreye TGT Surgical System in patients with glaucoma. The ADAPT trial is a prospective, multicenter, nonrandomized, open-label study enrolling 70 refractory glaucoma patients…